Nellcor/Masimo
This article was originally published in The Gray Sheet
Executive Summary
Tyco/Nellcor will pay Masimo an ongoing royalty for the right to sell its new line of pulse oximetry products under a patent litigation settlement announced Jan. 23. All pending litigation between the market rivals is dismissed (1"The Gray Sheet" April 5, 2004, p. 26). Nellcor has paid Masimo $265 mil. for damages and $65 mil. in advanced royalties as of Jan. 31...
You may also be interested in...
Nellcor Seeks Reversal Of $134 Mil. Pulse Oximeter Infringement Jury Award
Tyco unit Nellcor could face treble damages and an injunction against sales following a recent jury finding of willful infringement of four Masimo pulse oximetry patents, according to Masimo
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.